The driver for me are the Sheeba results. This has been mentioned by posters and management before, but I will say it again... the heavily pre-treated AML patients shouldn’t have had a response to bisantrene. All we wanted to know is that the drug is relatively safe. But one of ten had a complete response and 3 had a partial response. We also saw a response from those patients who had breast CA. And on top of all these, we’ve got new findings from City of Hope that low-dose bisantrene can be effective in treating AML through a different mechanism of action.
The directors and not selling, some of them are even buying, and we’ve got a hedge fund who bought heaps at 30c.
And we have a 5-path strategy that will generate lots of news.
$1 is easy, $2 is likely, and $4 is possible
RAC Price at posting:
79.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)